BMS-986408 + nivolumab

BMS-986408 + nivolumab is an investigational **combination therapy** for advanced solid tumors, currently in Phase 1/2 clinical trials. It consists of BMS-986408, a first-in-class small molecule inhibitor of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and nivolumab, a monoclonal antibody that acts as a programmed death-1 (PD-1) immune checkpoint inhibitor. BMS-986408 enhances T-cell response by inhibiting DGKα/ζ, thus amplifying anti-tumor immunity, especially in combination with PD-1 blockade. Nivolumab blocks PD-1, enabling immune cells to attack tumor cells. The combination is designed to synergistically improve immune-mediated tumor destruction in patients with advanced, unresectable, or metastatic solid malignancies[1][2][4][6][7].

Other names

BMS-986408 + nivolumabBMS-986408 + Opdivo